Short answer
Orthofix Medical Inc. (OFIX) filed an 8-K current report with the SEC on April 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Preliminary net sales cover the quarter ended March 31, 2026.
Orthofix Medical Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Preliminary net sales cover the quarter ended March 31, 2026
- Exhibit 99.1 contains the company’s April 9, 2026 news release with sales details
Item 5.02 · Departure/Election of Directors or Officers
- Max Reinhardt, President of Global Spine, departing executive role and employment around June 12, 2026
- Departure expected to qualify as termination without Cause or resignation for Good Reason
- Severance payments and benefits expected under his change-in-control and severance agreement
- Global Spine leadership transition risk for execution and operating continuity
Item EX-99.1 · Exhibit EX-99.1
- Spine leadership streamlined by eliminating the Global Spine Solutions president role, placing key leaders under CEO Massimo Calafiore
- Preliminary Q1 2026 net sales $196.7M, up 1.6% reported and 3.8% pro forma versus Q1 2025
- M6 discontinuation reduced reported sales by $4.1M year over year, masking underlying pro forma growth
- 2026 revenue guidance reaffirmed at $850M-$860M, implying 5.5% midpoint pro forma constant-currency growth
- Adjusted EBITDA guidance $95M-$98M, representing 70 basis points of margin expansion at midpoint; positive free cash flow expected excluding legal settlements
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Orthofix Medical Inc. 8-K filings
Get the next OFIX 8-K as it lands
Follow OFIX for push alerts, or ask the research agent what this filing means.